Fenofibrate suppresses the progression of hepatoma by downregulating osteopontin through inhibiting the PI3K/AKT/Twist pathway.

Authors:
Chen W; Chen F; Gong M; Ye L; Weng D and 2 more

Journal:
Naunyn Schmiedebergs Arch Pharmacol

Publication Year: 2023

DOI:
10.1007/s00210-023-02604-4

PMCID:
PMC10791796

PMID:
37566308

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Naunyn Schmiedebergs Arch Pharmacol

Abbreviation: Naunyn Schmiedebergs Arch Pharmacol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Pharmacology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Agomelatine improves memory and learning impairments in a rat model of LPS-induced neurotoxicity by…
Abdelaziz M; Mohamed AF; Zaki HF and 1 more (2023) - Transparency Score: 3/6
A highlight on carbamazepine-induced adverse drug reactions in Saudi Arabia: a retrospective medica…
Sukkarieh HH; Khokhar AA; Bustami RT and 3 more (2023) - Transparency Score: 2/6
A review of the bioactive components and pharmacological properties of Lavandula species.
Batiha GE; Teibo JO; Wasef L and 7 more (2023) - Transparency Score: 3/6
A survey of the currently known mast cell mediators with potential relevance for therapy of mast ce…
Molderings GJ; Afrin LB. (2023) - Transparency Score: 3/6
Berberine attenuates uric acid-induced cell injury by inhibiting NLRP3 signaling pathway in HK-2 ce…
Zheng J; Gong S; Wu G and 9 more (2023) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approvalAll animal experiments performed in this study were authorized by the ethical committee of Zhejiang Eyong Pharmaceutical Research and Development Center and conducted according to the guidelines for care and use of laboratory animals and the principles of laboratory animal care and protection. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

Evidence found in paper:

"Funding This work was supported by grants from the Project of Hangzhou Municipal Health Commission (Grant No. 0020190145)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025